問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of General Surgery

Division of Gastroenterological Surgery

Division of Cardiovascular Diseases

Division of Others-

China Medical University Hospital-Taipei (在職)

Division of Gastroenterological Surgery

更新時間：2023-09-19

鄭隆賓Jeng, Long-Bin
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

Recruiting Trial

8Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鄭隆賓

List

27Cases

2017-11-01 - 2021-05-20

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated9Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2014-04-20 - 2016-05-20

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2022-06-01 - 2026-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2021-08-01 - 2024-08-01

Phase I/II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2022-09-15 - 2023-04-25

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2009-10-31 - 2012-10-20

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2011-01-01 - 2017-12-31

Phase III

A prospective, randomized, double-blind, placebo-controlled, parallel-group, international multicenter phase III trail of PI-88 in the adjuvant treatment of subjects with hepatitis virus related hepatocellular

  • Condition/Disease

    Postoperative adjuvant therapy for hepatitis virus-related liver cancer

  • Test Drug

    PI-88 or matching placebo

Participate Sites
9Sites

Terminated9Sites

2017-12-01 - 2018-12-20

Others

A Retrospective Chart Review Study of Patients Who Previously Participated in the PATRON Phase III Trial

  • Condition/Disease

    Adjuvant treatment of Post- Resection Hepatocellular Carcinoma

  • Test Drug

    Muparfostat (PI-88)

Participate Sites
10Sites

Terminated8Sites

Study ended1Sites

鄭隆賓
China Medical University Hospital

Division of Others-

2019-02-01 - 2019-12-25

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2018-09-01 - 2022-12-31

Phase II

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞

Participate Sites
9Sites

Recruiting8Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB